-
1.发明公开
公开(公告)号：EP2117593A1
公开(公告)日：2009-11-18
申请号：EP08733553.5
申请日：2008-03-10
申请人： Hoffman-La Roche AG
发明人： YOUNG, David, S.F. , SAYEGH, Daad , FAN, Sheung, Tat , POON, Ronnie, Tung, Ping , LEE, Trence, Kin, Wah
IPC分类号： A61K39/395 , A61K47/48 , A61K51/10 , A61P35/00 , A61P35/04 , A61P37/04 , G01N33/574 , G01N33/577
CPC分类号： C07K16/30 , A61K47/6849 , A61K49/0013 , A61K2039/505 , C07K16/2884 , C07K2317/24 , G01N33/574 , G01N33/57492 , G01N2333/70585
摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
摘要翻译： 本发明涉及癌症疾病的诊断和治疗，特别涉及原发性和转移性人肿瘤细胞的细胞毒性介导; 并且最具体地涉及使用分离的单克隆抗体或其癌性疾病修饰抗体（CDMAB），任选地与一种或多种化疗剂组合作为在这样的人类肿瘤例如人类肿瘤中启动细胞毒性应答的手段。 由肝细胞产生的任何原发性或转移性肿瘤部位。 本发明进一步涉及利用本发明的CDMAB的结合测定。
-
2.发明公开
公开(公告)号：EP1688180A1
公开(公告)日：2006-08-09
申请号：EP05100801.9
申请日：2005-02-04
IPC分类号： B01L3/02
CPC分类号： B01L3/0279
摘要： The present invention is directed to a pipette comprising mounting surfaces of different diameter for the use of disposable tips of different size, which allows to easily discarding the tips after use. Such pipettes can be used in manual and automatic pipetting systems.
摘要翻译： 本发明涉及移液管，其包括安装不同直径的表面以使用不同尺寸的一次性尖端，这允许在使用后容易地丢弃尖端。 这种移液器可用于手动和自动移液系统。
-
3.发明公开
公开(公告)号：EP1639356A2
公开(公告)日：2006-03-29
申请号：EP04817702.6
申请日：2004-06-18
发明人： BHULLAR, Raghbir, S. , DIEBOLD, Eric, R. , HILL, Brian, S. , SURRIDGE, Nigel , WALLING, Paul, Douglas
IPC分类号： G01N27/30 , G01N27/327 , C12Q1/00
CPC分类号： G01N33/5438 , C12Q1/001 , G01N27/3272 , H05K1/0393 , H05K3/027 , Y10T29/49007 , Y10T29/49117 , Y10T29/49155 , Y10T29/49156
摘要： A method of making a biosensor is provided. The method includes providing an electrically conductive material on a base and partially removing the conductive material using laser ablation from the base so that less than 90% of the conductive material remains on the base and at least one electrode pattern is formed from the conductive material. The at least one electrode pattern has an edge extending between two points. A standard deviation of the edge from a line extending between two points is less than about 6 mum along the length of the edge.
摘要翻译： 提供了一种制造生物传感器的方法。 该方法包括在导电材料的基础上提供和部分地去除使用激光烧蚀从所以没有低于90％的导电材料的保持在基座上，且至少一个电极图案由导电材料形成的基体的导电材料。 所述至少一个电极图案具有到边缘的两个点之间延伸。 从线的两个点之间延伸的边缘的标准偏差小于沿边缘的长度的大约6沉默。
-
4.发明公开SYSTEM AND METHOD FOR ANALYTE MEASUREMENT OF BIOLOGICAL FLUIDS USING DOSE SUFFICIENCY ELECTRODES 审中-公开系统和方法使用剂量充分电极分析生物液体
公开(公告)号：EP1639355A1
公开(公告)日：2006-03-29
申请号：EP04776822.1
申请日：2004-06-18
IPC分类号： G01N27/30 , G01N27/02 , G01N27/327 , G01N33/487
摘要： A method of measuring an analyte in a biological fluid comprises applying an excitation signal having a DC component and an AC component. The AC and DC responses are measured; a corrected DC response is determined using the AC response; and a concentration of the analyte is determined based upon the corrected DC response. Other methods and devices are disclosed.
-
5.发明公开VERFAHREN UND VORRICHTUNG ZUR BESTIMMUNG EINES LICHTTRANSPORTPARAMETERS UND EINES ANALYTEN IN EINER BIOLOGISCHEN MATRIX 有权方法和一种用于确定光传输和参数分析物在生物MATRIX
公开(公告)号：EP1463443A2
公开(公告)日：2004-10-06
申请号：EP02795119.3
申请日：2002-12-07
IPC分类号： A61B5/00
CPC分类号： A61B5/1455 , A61B5/0059 , A61B5/14532 , A61B2562/0233 , A61B2562/0242 , A61B2562/043 , G01N21/49
摘要： The invention relates to a method for selectively determining the index of dispersion µs in a biological dispersion matrix, especially for the non-invasive determination of the concentration of glucose in the skin, with the aid of detection measuring, whereby respective light is radiated as a primary light (9) in the biological matrix (5) and measurement occurs for an intensity measuring value of exposed secondary light (12) exiting from a detection point (33-40), which is disposed at various measuring distances (ρ) from the respective point of radiation (10) during said detection measurements. In order to improve the quality and selectivity of the determination of µs, the primary light is radiated by means of a contacting light guiding element at an oblique angle of between 5° and 85°. At least two detection measurements of the measuring interval (ρ) between the respective radiation point (10) and the respective detection point (33-40) corresponds to a maximum five fold value of the average path length of the propagating light in the biological matrix.
-
公开(公告)号：EP1401813A1
公开(公告)日：2004-03-31
申请号：EP02735394.5
申请日：2002-05-29
发明人： BEARD, Colin, Charles , CLARK, Robin, Douglas , FISHER, Lawrence, Emerson , HARRIS, Ralph, New, III , REPKE, David, Bruce
IPC分类号： C07D209/30 , A61K31/496 , C07D403/04 , A61P25/00
CPC分类号： A61K31/405 , C07D209/30 , C07D401/04 , C07D401/12
摘要： This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula (I), wherein one of R?5, R6 or R7¿ is a group of general Formula (B), wherein W is a -CH-group or a nitrogen atom, and the other substituents are as defined herein; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically aceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, Their use as therapeutic agents, and methods of preparation thereof.
-
公开(公告)号：EP1705480A1
公开(公告)日：2006-09-27
申请号：EP05102290.3
申请日：2005-03-22
发明人： Pachl, Rudolf, Dr. , Griesheimer, Hans-Ludwig , Schmid, Wilfried, Dr. , Frank, Martin , Hoferer, Jürgen , Babic, Branislav
IPC分类号： G01N27/327 , A61B5/145 , B01L3/00
CPC分类号： B01L3/5023 , B01L2200/141 , B01L2300/0825 , G01N33/558 , Y10T29/49982 , Y10T436/144444
摘要： Ein analytisches Testelement (1) zur Bestimmung eines Analyten in einer Körperflüssigkeit, das einen Nachweisbereich (14) in dem das Analyt nachgewiesen wird, und einen Auftragungsort (3) beinhaltet, an dem die Körperflüssigkeit auf das Testelement (1) aufgebracht werden kann, wobei der Nachweisbereich (14) von dem Auftragungsort (3) beabstandet ist, wobei eine auf den Auftragungsort (3) aufgegebene Körperflüssigkeit vom Auftragungsort (3) zumindest zum Teil zum Nachweisbereich (14) gelangt. Das Testelement beinhaltet weiterhin einen Kontaminationsbereich, der zumindest zum Teil an den Auftragungsort angrenzt, wobei auf dem Kontaminationsbereich des Testelements zumindest zum Teil eine Haftsubstanz, vorzugsweise Polyvinylacetat, aufgebracht ist, wobei die Haftsubstanz an dem Kontaminationsbereich des Testelementes haftet und weiterhin fähig ist, mit einer auf dem Testelement überflüssig aufgetragenen Körperflüssigkeit in der Weise wechselzuwirken, dass die Körperflüssigkeit auf dem Testelement zumindest zum Teil haftet, so dass überflüssig aufgetragene Körperflüssigkeit am Kontaminationsbereich verbleibt. Insbesondere betrifft die Erfindung Testelemente, die nach Gebrauch in einem Vorratsbehälter bevorratet werden. Darüber hinaus beschreibt die Erfindung die Herstellung solcher Testelemente.
摘要翻译： 用于测定体液中的分析物的测试条，包括样品施用部位（3）和与其分离的测试部位，以及围绕施用部位的污染区域（7），所述污染区域涂覆有粘合剂，过量样品在其上附着 干燥，是新的。 包括以下独立权利要求：（1）在测试条中使用聚乙酸乙烯酯作为粘合剂材料; （2）测试条的生产，包括将粘合剂材料施加到污染区域，将其干燥; （3）用盖子（2）安装测试条; （4）测试条的生产，包括在将粘合剂施加到污染区之前或之后将试剂施加到测试部位; （5）用于测试条的杂志; 和（6）由测试条和杂志组成的系统，使用后放置条带。
-
公开(公告)号：EP1501826B1
公开(公告)日：2006-09-27
申请号：EP03714714.7
申请日：2003-01-23
IPC分类号： C07D403/06 , C07D413/14 , C07D495/04 , A61K31/4178 , A61P13/00
CPC分类号： C07D403/06 , C07D495/04
摘要： This invention relates to compounds which are alpha-1 receptor agonists, preferably alpha- 1A/L receptor agonists, and which are represented by the general formula I wherein X is -S(O)n- or -C(O)-, A is (CI-6)-alkyl, aryl, heteroaryl, hydroxy(C 1-6)-alkyl, or -(CH2)p-NRaRb, and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, their preparation and their use as therapeutic agents.
-
公开(公告)号：EP1636223A1
公开(公告)日：2006-03-22
申请号：EP04732950.3
申请日：2004-05-14
IPC分类号： C07D417/14 , C07D491/10 , C07D417/04 , A61K31/428 , A61P25/28
CPC分类号： C07D417/04 , C07D417/14 , C07D491/10
摘要： The invention relates to compounds of the general formula (I) wherein R1 is 1,4-dioxepanyl or tetrahydropyran-4-yl; R 2 is -N(R)-(CH2)n,-5-or 6 membered non aromatic heterocycle, optionally substituted by one or more substituents, selected from the group consisting of lower alkyl or -NR2, or is - (CH2)n-5-or 6 membered non aromatic heterocycle, optionally substituted by -(CH2)n-OH, lower alkyl, lower alkoxy, or is -CH2)n-5-or 6 membered aromatic heterocycle, optionally substituted by lower alkyl, lower alkoxy, halogen, halogen-lower alkyl, -CH2N(R)(CH2)20CH3, -N(R)(CH2)20CH3, -CH2-morpholinyl or -CH2-pyrrolidinyl or is (CH2)n-cycloalkyl, optionally substituted by hydroxy, or is -N(R)-cycloalkyl, optionally substituted by hydroxy or lower alkyl, or is phenyl, optionally substituted by lower alkoxy, halogen, halogen-lower alkyl, lower alkyl, -CH2-pyrrolidin-1-yl, -CH2-morpholinyl, -CH2N(R)(CH2)20CH3 or -CH2-N(R)C(O)-lower alkyl, or is 1,4-dioxa-8-aza-spiro[4,5]decane, or is 2-oxa-5-aza-bicyclo[2.2.1]heptane, or is I-oxa-8-aza-spiro[4,5]decane, or is -N(R)-7-oxa-bicyclo [2.2. 11 hept-2-yl, or is 2-aza-bicyclo[2.2.2]decane; R is hydrogen or lower alkyl; n is 0 or 1; and pharmaceutically acceptable acid addition salts thereof for the treatment of diseases, which relate to the A2A receptor.
-
公开(公告)号：EP1456202A1
公开(公告)日：2004-09-15
申请号：EP02805304.9
申请日：2002-12-05
IPC分类号： C07D417/04 , A61K31/428 , A61P25/00
CPC分类号： C07D417/04 , C07D277/84 , C07D417/12 , C07D417/14
摘要： The present invention relates to compounds of the general formula (1), wherein R1 3,6-dihydro-2H-pyran-4-yl, 5,6-dihydro-4H-pyran-3-yl, t,6-dihydro-4H-pyran-2-yl, tetrahydropyran-2,3 or 4-yl, cyclohex-1-enyl, cyclohexyl or is 1,2,3,6-tetrahydro-pyridin-4yl or piperidin-4-yl, which are optionally substituted C(O)CH3in the 1-position of the N-atom; R2 is lower alkyl, piperidin-1yl, optionally substituted by hydroxy, or is phenyl, optionally substituted by (CH2)n-N(R')-C(O)-(CH2)n-NR'2,-(CH2)n-halogen, lower alkyl or (CH2)n-O-lower alkyl, or is morpholinyl or is pyridinyl, which is optionally substituted by halogen, -N(R')-(CH2)n-O-lower alkyl, lower alkyl, lower alkoxy, morpholinyl or (CH2)n-pyrrolidinyl; n is 0, 1 or 2; R' is hydrogen or lower alkyl, and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compounds of general formula I are adenosine receptor ligands. Specifically, the compounds of the present invention have a good affinity to the A2A-receptor and they may be used in the treatment of diseases, related to this receptor.
-
-
-
-
-
-
-
-
-
搜索结果
34 条记录 (耗时 0.02 秒)
